2010 Fiscal Year Final Research Report
Molecular analysis of lung adenocarcinomas that do not have mutations in the EGFR pathway and development of therapeutic strategies against them
| Project/Area Number |
20390376
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Aichi Cancer Center Research Institute |
|---|
Principal Investigator |
MITSUDOMI Tetsuya Aichi Cancer Center Research Institute, 分子腫瘍学部, 研究員 (70209807)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YATABE Yasushi 愛知県がんセンター研究所, 分子腫瘍学部, 研究員 (90280809)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | 呼吸器外科学 / 分子標的治療 / 個別化医療 |
|---|
| Research Abstract |
EGFR tyrosine kinase inhibitor confers often dramatic response in lung cancer harboring EGFR mutation. However, virtually all the tumors acquire resistance. For large fraction of lung cancer, a efficacious therapeutic target is not known. In this study, we confirmed the HER2 mutation or MET amplification could be the therapeutic target although their incidences were low. Furthermore, we found a reciprocal relationship between T790M secondary mutation of the EGFR gene and MET amplification in acquire resistance.
|
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Book] Lippincott Williams & Wilkins2010
Author(s)
Hirsch FR, Mitsudomi T
Total Pages
717-739
Publisher
Janne PA. Chapter 49, Anti-EGFR therapies : How to select patients. In : Pass H, Carbone DP, Johnson DH, Minna JD, Turrisi AT, Scagliotti GV, editors. Principles and Practice of Lung Cancer. 4th ed. Baltimore
